Cachexia drug treatment
Also called: appetite stimulants, anti-cachexia drugs.
Last reviewed 2026-09-16. How this works.
Treating cachexia Grade C
Human evidence exists and does not settle it.
The muscle loss that comes with cancer is real and well understood, but no one drug has been shown to fix it.
No single agent established. The problem itself is real and well understood.
The claim
The claim is that the weight and muscle loss of advanced cancer can be treated with a drug, usually an appetite stimulant.
What it does
Cachexia is not simple undereating. The agreed definition describes ongoing loss of skeletal muscle that cannot be fully reversed by conventional nutritional support, which is why eating more does not solve it and why people who are told to try get frustrated.1
The evidence
The position of current clinical reviews is that no single agent has been established as effective. Agents remain in development, and this is an area where the position may change.3
There is a separate problem worth knowing about, which is that cachexia is under-recognised. In metastatic bowel cancer, 52 percent of people met the consensus criteria while 9 percent were identified by the oncologist's clinical assessment. If it is not named it is not treated.2
What is absent
No single drug has been established as effective for cancer cachexia. This is not a compound nobody has examined; it is a problem that has been examined and not yet solved.
Scope: any single agent for cancer cachexia.
Established by published review, current clinical reviews of the field, as recorded in chapter 11 note 8, checked 2026-09-16. Result: no single agent established as effective.3
What to ask
Is what is happening to my weight and muscle something you would call cachexia, and is there anything you would offer for it?
The dish-to-person gap
This entry covers a group of drugs rather than one compound, so no single pharmacokinetic profile applies to it.
When to call your team — no warning signs are recorded
Whatever you are taking or thinking of taking, the people treating you can only weigh it if they know about it. That is true when nothing has been written down here, and it is most true then.
The register records no warning signs for this entry. Anyone losing weight during treatment should tell their team, because it is treatable and because it changes what the team can offer.
Interactions
This entry covers a group of agents rather than one compound, and the register does not hold an interaction profile for it.
Nobody having looked is not the same as nothing being there. That is what this line says and all it says.
The whole interaction list, and how to turn it into a pharmacy review request.
Find a trial instead
Agents remain in development, so this is an area where a trial is a genuine option and where the position may change.
Search ClinicalTrials.gov for recruiting studies of cancer cachexia OR cachexia
A trial is the same decision with monitoring, a known preparation and a doctor who knows what else you are taking.
References
Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncology 2011;12:489-495.
No persistent identifier recorded.
How this was reached: transcribed from chapter note, via docs/CHAPTER-NOTES.json, chapter 11 note 1. The author string is abbreviated in the source that was read and has not been expanded.
Cancer cachexia: identification by clinical assessment versus international consensus criteria in patients with metastatic colorectal cancer. Nutrition and Cancer, 2018.
doi:10.1080/01635581.2018.1504092
How this was reached: transcribed from chapter note, via docs/CHAPTER-NOTES.json, chapter 11 note 9.
The position described in current clinical reviews of cancer cachexia, that no single agent has been established as effective.
No persistent identifier recorded.
How this was reached: transcribed from chapter note, via docs/CHAPTER-NOTES.json, chapter 11 note 8.